
Opinion|Videos|July 15, 2024
Meeting Unmet Needs for Patients With RCC
Author(s)Martin H. Voss, MD
Martin H. Voss, MD, discusses the trajectory of the advanced renal cell carcinoma treatment landscape and provides clinical advice to community oncologists.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- What are the current unmet needs for patients with renal cell carcinoma (RCC)?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
3
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5



























